This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novo Nordisk accused in US court of delaying generic competition for GLP-1 drug

( January 23, 2026, 19:24 GMT | Official Statement) -- MLex Summary: Novo Nordisk has been accused in a US complaint of illegally delaying generic competition for its branded GLP-1 drug Victoza. The complaint claims that Novo used a delay it bought from Teva through an illegal reverse payment to switch prescriptions from the Victoza liraglutide market, which faced imminent generic competition, to the Ozempic semaglutide market, which did not similarly face such competition.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections